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ORIGINAL ARTICLE

A novel prognostic model predicting overall survival in patients
with metastatic castration‐resistant prostate cancer receiving
standard chemotherapy: A multi‐trial cohort analysis
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Abstract
Purpose: Generalizable, updated, and easy‐to‐use prognostic models for patients with
metastatic castration‐resistant prostate cancer (mCRPC) are lacking. We developed a
nomogram predicting the overall survival (OS) of mCRPC patients receiving standard
chemotherapy using data from five randomized clinical trials (RCTs).
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Methods: Patients enrolled in the control arm of five RCTs (ASCENT 2, VENICE,
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CELGENE/MAINSAIL, ENTHUSE 14, and ENTHUSE 33) were randomly split
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between training (n = 1636, 70%) and validation cohorts (n = 700, 30%). In the
training cohort, Cox regression tested the prognostic significance of all available
variables as a predictor of OS. Independent predictors of OS on multivariable
analysis were used to construct a novel multivariable model (nomogram). The
accuracy of this model was tested in the validation cohort using time‐dependent
area under the curve (tAUC) and calibration curves.
Results: Most of the patients were aged 65–74 years (44.5%) and the median
(interquartile range) follow‐up time was 13.9 (8.9–20.2) months. At multivariable
analysis, the following were independent predictors of OS in mCRPC patients: sites
of metastasis (visceral vs. bone metastasis, hazard ratio [HR]: 1.24), prostate‐specific
antigen (HR: 1.00), aspartate transaminase (HR: 1.01), alkaline phosphatase (HR:
1.00), body mass index (HR: 0.97), and hemoglobin (≥13 g/dl vs. <11 g/dl, HR: 0.41;
all p < 0.05). A nomogram based on these variables was developed and showed
favorable discrimination (tAUC at 12 and 24 months: 73% and 72%, respectively)
and calibration characteristics on external validation.
Conclusion: A new prognostic model to predict OS of patients with mCRPC
undergoing first line chemotherapy was developed. This can help urologists/
oncologists in counseling patients and might be useful to better stratify patients for
future clinical trials.
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| INTRODUCTION

2 |

Prostate cancer, with 191,930 and 33,330 estimated new cases

ET AL.

M A T E R I A L S AN D M E T H O D S

2.1 |

Data source

and deaths, respectively, in the United States during 2020,
represents a national and global concern.1 For patients with

The data set used in this study was obtained merging the Prostate Cancer

locally advanced or metastatic disease, androgenic deprivation

Dialogue for Reverse Engineering Assessments and Methods (DREAM)

2

therapy (ADT) is an effective treatment. However, in the context

Challenge database16 with the control arm of the ENTHUSE 14 trial17

of chronic androgen depletion, sooner or later, the disease

database. Both these databases are available on the Project Data Sphere

develops mechanisms capable of making cell proliferation

platform

independent from the driving force of the androgens. This late

pcdc). The latter is a free digital library‐laboratory where researchers

phase of the disease is known as castration‐resistant prostate

can share and analyze data from Phase III cancer clinical trials.

(https://www.projectdatasphere.org/projectdatasphere/html/

cancer (CRPC). The latter is a hard‐to‐manage disease that

The DREAM challenge data set includes data from four control

eventually leads to a grim prognosis. The median survival in

arms of the following clinical trials: ASCENT 2, CELGENE/MAINSAIL,

these patients ranges from 9 to 30 months and further decreases

VENICE, and ENTHUSE 33.18–21 Demographic, clinical, and patho-

3

to 9–13 months in the metastatic stage (mCRPC). The aggres-

logical variables were extracted from the final data set.

siveness of the disease varies in this population of patients and
the underlying causes of this variability are not yet fully

2.2 |

understood.

Population

Several drugs have been developed for the treatment of
these patients. Therapeutic schemes are based on the combined

The five trials used in this study had similar inclusion and exclusion

and sequential use of chemotherapeutic agents (docetaxel and

criteria. In particular, patients were aged ≥ 18 years, chemonaïve,

cabazitaxel), new molecules disrupting the androgen axis (en-

with progressive mCRPC, with an adequate hematologic, cardiac,

zalutamide,

immunotherapy

renal, and hepatic function, presenting an Eastern Cooperative

(Sipuleucel‐T), and bone‐targeting drugs (Radium‐223). Despite

Oncology Group (ECOG) between 0 and 2.18–21 Patients enrolled in

these advances, many Phase I and II trials investigating these

these control arms received the standard docetaxel‐based chemo-

treatments have shown limited benefits in mCRPC patients. 4 As

therapy with glucocorticoids or standard supportive/palliative treat-

well, being the only Food and Drug Administration‐approved

ment. Of note, patients enrolled in the ENTHUSE 33 trial were

cancer vaccine, Sipuleucel‐T has limited use clinically. In a Phase

symptomatic, whereas only asymptomatic or mildly symptomatic

III trial, overall survival (OS) was only 2.8 months more in the

patients were enrolled in the ENTHUSE 14 trial. Moreover, these two

Sipuleucel‐T arm compared with placebo, in high‐quartile

trials included only patients with metastasis to bone and/or visceral

prostate‐specific antigen (PSA) and 13 months in the lower

but excluded patients with lymph node only involvement. The

PSA.4,5 However, its use is quite limited, where in a real‐world

detailed description of inclusion and exclusion criteria is reported in

study of 7272 mCRPC patients, only 10% were treated with

Supporting Information: Table 1 and 2. We excluded from the study a

Sipuleucel‐T.

abiraterone,

4–6

and

apalutamide),

More recently developed therapeutics include

antibody‐drug conjugates, with five types currently in Phase 1

total of 69 patients (49 in the training and 20 in the testing cohort)
because of missing values (Figure 1).

trials in mCRPC patient population.7 In the setting of a vast array
of therapeutics, the application of reliable prognostic model
would permit the assignment of patients into risk classes. This in

2.3 |

Covariates

turn can yield a more accurate risk‐benefit assessment of the
current therapies and might help identifying the most suitable

In this study, we employed patient‐level variables, including age

timing or indication of these. Moreover, such a model can have a

(18–64, 65–74, and ≥75 years), race (White, Asian, and Others), body

critical role in the study design of future clinical trials investigat-

mass index (BMI), and the ECOG scale of performance status (from 0

ing the efficacy of new interventions.

to 2). Noteworthy, we were unable to discern the Black race as a

For the aforementioned reasons, several models predicting

separate category, because this was not done in the included trials.

cancer control outcomes in mCRPC patients were developed over

We also included information regarding the pathological sites of

the years.8–15 However, none of these showed enough reliability to

metastasis. This last variable was defined hierarchically based on the

make it universally accepted and broadly applicable in a real‐world

most advanced metastatic stage as follows: visceral versus bone

setting. Moreover, virtually all of these models are outdated or were

versus lymph nodes metastasis. Finally, we also abstracted laboratory

based on a limited sample size. To circumvent these limitations, our

variables, which consisted of PSA, white blood cells, neutrophils,

objective was to develop an updated and easy‐to‐use prognostic

platelets (PLTs), hemoglobin (<11, 11–12.9, and ≥13 g/dl), creatinine,

model to predict OS among mCRPC patients employing a large data

alanine transaminase, aspartate transaminase (AST), total bilirubin,

pool derived from the control arm of five randomized clinical

calcium, and alkaline phosphatase (ALP). Hemoglobin was stratified

trials (RCTs).

according to the World Health Organization criteria for the diagnosis

MODONUTTI
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F I G U R E 1 Flowchart describing the selection process of the patients included in this study. [Color figure can be viewed at
wileyonlinelibrary.com]

of anemia.22 We merged the categories <8 and 8–10.9 mg/dl in a

differences in categorical and continuous variables using the χ2 test

single group (<11 mg/dl) because of the low number of patients

and analysis of variance test, respectively.

presenting with such values of hemoglobin.

Our statistical analysis consisted of several steps. First, we
randomly split our cohort into a training cohort, which included 70%
of our original cohort, and a validation cohort, which included the

2.4

| Endpoints

remaining 30%. Second, we performed a univariable Cox regression
to test the prognostic significance of each of our covariates as a

The outcome of interest in this study was the OS of mCRPC patients,

predictor of OS. Depending on the distribution, highly skewed

calculated from the time of randomization to time of death, and/or

variables underwent a restricted cubic spline transformation to

last available follow‐up.

achieve a better fit. Third, we utilized only the variables that reached
a statistical significance status at univariable analysis to develop a
multivariable model predicting OS, based on Cox regression. Linear

2.5

| Statistical analysis

assumption was examined not only with the distribution of the
variables but also with the proportional hazard assumptions in COX

We reported categorical variables using frequencies and percentages,

PH models and the assumptions were appropriate for other

while continuous variables were reported using median and inter-

continuous variables. Finally, we ran multiple sensitivity analyses to

quartile ranges (IQRs). We tested the statistical significance of

test the robustness of our results. The discrimination of the novel

1296
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model was tested using the time‐dependent area under the curve

analysis were used to develop our novel nomogram (Figure 2)

(tAUC). Time‐dependent receiver operating characteristic curves for

predicting OS in mCRPC patients.

censored survival data was estimated using Kaplan–Meier (KM)
method.23 Furthermore, the calibration of our prognostic model was
tested by comparing the predicted survival probability with the actual

3.3 |

Nomogram validation

survival of the training and validation cohorts. Finally, KM curves
were used to depict the OS in our validation cohort, after stratifying

The tAUC for the training cohort at 12, 24, 36, and 48 months were

patients into low‐ versus high‐risk groups based on the median

0.74, 0.73, 0.72, and 0.67, respectively. In the validation cohort

predicted value of our novel nomogram. The data analysis was

(n = 680), the tAUC was 0.71, 0.68, 0.77, and 0.78, respectively, for

performed using SAS® software 9.4 (SAS Institute). The statistical

the same time period (Figure 3). The calibration of our model was

significance of the two‐sided p was set at ≤0.05.

favorable, as shown in Figure 4A,B. We used KM survival curves to
depict survival of patients categorized in low‐ versus high‐risk groups,
based on median predicted OS (81%) of our novel nomogram in the

3

| RESULTS

training cohort. The 2‐year OS rate in the low‐risk versus high‐risk
groups was 59.9% versus 27.7% (log‐rank p < 0.0001) in the training

3.1

| Patient characteristics

cohort and 56.8% versus 29.3% (log‐rank p < 0.0001) in the validation
cohort (Figure 5A,B). From Figure 5A,B, the KM plots show that few

The descriptive data of our population are reported in Table 1.

patients are at risk after 2 years and the SEs are large for 3‐ and

Overall, 80.5% of patients were White, the majority aged between 65

4‐year tAUC. The tAUC at 3 and 4 years are not significantly different

and 74 years (44.5%), with a median BMI of 27.2 (IQR: 24.7–30.3),

in training and testing data set.

and an ECOG performance status of 0 (51.1%) or 1 (45.9%).
The median (IQR) PSA was 81.7 ng/ml (29.0–239.1 ng/ml) and
59.4% of the patients presented bone metastasis with or without

3.4 |

Sensitivity analysis

lymph node involvement. The median (IQR) hemoglobin at the
baseline was 12.7 g/dl (11.6–13.6 g/dl), the median (IQR) creatinine

The 12‐months tAUC was tested separately within each sub‐cohort

was 82.0 µmol/L (71.0–97.0 µmol/L), and the median (IQR) ALP was

of the five included trials and resulted in the range between 0.71

132.0U/L (85.0–263.0 U/L).

and 0.77. Similarly, when patients were divided into two subcohorts

The median (IQR) length of follow‐up was 14 (9.1–19.9) months
for the overall cohort. This was 14 (9.1–19.9) months for the training

based on metastasis sites (visceral, bone, and lymph nodes) the
12‐month tAUC value ranged between 0.68 and 0.73.

cohort and 13.8 (8.6–20.8) months for the validation cohort.

4 |
3.2

D IS CU SS IO N

| Nomogram development
Metastatic CRPC represents the most advanced stage of prostate

In the training cohort (n = 1587 patients), the following variables were

cancer. During the last decades, many new treatments have been

significant as predictors of OS on univariable analysis: age (only ≥ 75

developed to improve the survival of these individuals. That said, the

years), BMI, ECOG performance status, PSA, sites of metastasis, PLT,

probability of OS in these patients is heterogeneous and depends on

hemoglobin, neutrophils, AST, ALP, and calcium (Table 2, all p < 0.05).

several clinical and pathological features at the time of diagnosis.

Due to the skewed distribution, PSA, PLT, and calcium underwent

Unfortunately, the literature is scarce in models predicting the OS of

restricted cubic spline transformation. Cubic spline was used on PSA

such individuals. To fill this void, we developed, and externally

and ALP. The reported HR was the estimation at a specified PSA

validated, a “multi‐trial” based, user‐friendly nomogram.

value instead of the entire range, that is, PSA at 85 ng/ml and
specified ALP value of 131 U/L.

Several of our findings are worth highlighting. First, the overall
discrimination (tAUC) our model was high, in the range of 69%–78%

On multivariable Cox proportional hazard analysis (Table 2), only

(in the validation setting), with variations based on the predicted time

the following variables resulted as independent predictors of OS: ALP

point. Similar variations were observed in the calibration of the

(hazard ratio [HR]: 1.00; 95% confidence interval [CI]: 1.00–1.01), PSA

model. However, the overall calibration was favorable, as most

(HR: 1.00; 95% CI: 1.00–1.00), AST (HR: 1.01; 95% CI: 1.00–1.01),

predicting values were very close to the actual survival values.

BMI (HR: 0.97; 95% CI: 0.95–0.99), hemoglobin (≥13g/dl vs. <11 g/dl,

Second, age was not an independent predictor of OS in individuals

HR: 0.41; 95% CI: 0.32–0.51), and sites of metastasis (visceral vs.

with mCRPC, which implies that the survival of these patients is

bone, HR: 1.24; 95% CI: 1.06–1.44; all p < 0.05). Interestingly, bone

highly dictated by cancer survival. This is a key finding, as it implies

metastasis was not associated with a statistically significant higher OS

that attempts should be made to maximize cancer control in these

risk, when compared with lymph nodes metastasis only in these

individuals, regardless of their age. Third, in our report, higher BMI

patient settings (p = 0.55). Independent predictors on multivariable

was an independent predictor of more favorable OS. To the best of

2267 (100%)

Patients, n (%)

212 (9.4%)
230 (10.1%)

Asian

Others

69 (3.0%)

2

82.0 (71.0–97.0)
23.7 (16.9)

ALT, U/L (mean [SD])

253.0 (207.0–316.0)

943 (41.6%)

1009 (44.5%)

Creatinine, μmol/L (median [IQR])

PLT10 /L (median [IQR])

9

≥13 g/dl

11–12.9 g/dL

315 (13.9%)

12.7 (11.6–13.6)

Hemoglobin, g/dl (median [IQR])

<11 g/dl

4.65 (3.6–6.3%)

6.8 (5.5–8.6)

740 (32.6%)

1,346 (59.4%)

181 (8.0%)

Neutrophils, 10 /L (median [IQR]

9

WBC, 10 /L (median [IQR])

9

Any visceral

Bone w/o lymph nodes

Lymph nodes only

Metastasis sites, n (%)

81.7 (29.0–239.1)

1040 (45.9%)

1

PSA, ng/ml (median [IQR])

1158 (51.1%)

27.2 (24.7–30.3)

0

ECOG performance status, n (%)

BMI, kg/m2 (median [IQR])

563 (24.8%)

1,009 (44.5%)

65–74 years

≥75 years

695 (30.7%)

18–64 years

Age, n (%)

1825 (80.5%)

White

Race, n (%)

Overall

23.6 (17.1)

80.0 (70.0–93.0)

279.0 (229.0–350.0)

210 (41.6%)

214 (42.4%)

81 (16.0%)

12.7 (11.5–13.7)

4.9 (3.7–7.2)

7.0 (5.4–9.2)

187 (37.0%)

276 (54.7%)

42 (8.3%)

87.1 (33.7–275.0)

20 (4.0%)

237 (46.9%)

248 (49.1%)

27.8 (25.1–31.1)

106 (21.0%)

236 (46.7%)

163 (32.3%)

87 (17.2%)

0 (0.0%)

418 (82.8%)

505 (22.3%)

CELGENE/MAINSAIL

24.3 (15.4)

83.10 (71.0–97.2)

247.0 (205.0–308.0)

249 (42.9%)

262 (45.1%)

70 (12.0%)

12.7 (11.7–13.5)

4.43 (3.5–5.8)

6.9 (5.5–8.2)

241 (41.5%)

308 (53.0%)

32 (5.5%)

92.8 (30.9–261.4)

27 (4.6%)

287 (49.4%)

267 (46.0%)

27.3 (25.0–30.1)

122 (21.0%)

244 (42.0%)

215 (37.0%)

23 (4.0%)

36 (6.2%)

522 (89.8%)

581 (25.6%)

VENICE

25.4 (22.4)

82.0 (71.0–96.0)

248.0 (205.0–318.0)

176 (38.7%)

189 (41.5%)

90 (19.8%)

12.5 (11.3–13.5)

5.44 (4.2–7.5)

7.2 (5.9–9.5)

191 (42.0%)

264 (58.0%)

0 (0.0%)

101.0 (34.0–237.5)

0 (0.0%)

216 (47.5%)

239 (52.5%)

26.9 (24.3–29.7)

89 (19.6%)

213 (46.8%)

153 (33.6%)

62 (13.6%)

72 (15.8%)

321 (70.5%)

455 (20.1%)

ENTHUSE 33

22.5 (13.0)

81.0 (70.3–95.0)

0.035

<0.001

<0.001

0.001

<0.001

<0.001

<0.001

<0.001

<0.001

<0.001

<0.001

p

|
(Continues)

229.0 (191.5–273.0)

124 (48.1%)

117 (45.3%)

17 (6.6%)

12.9 (12.1–13.7)

4.22 (3.4–5.3)

6.6 (5.5–7.8)

86 (33.3%)

172 (66.7%)

0 (0.0%)

52.3 (16.8–155.0)

0 (0.0%)

70 (27.1%)

188 (72.9%)

26.1 (23.8–28.6)

95 (36.8%)

108 (41.9%)

55 (21.3%)

6 (2.3%)

99 (38.4%)

153 (59.3%)

258 (11.4%)

ENTHUSE 14

ET AL.

22.2 (13.6)

88.0 (75.8–106.0)

253.0 (207.0–308.5)

184 (39.3%)

227 (48.5%)

57 (12.2%)

12.6 (11.6–13.6)

4.4 (3.4–5.7)

6.6 (5.4–8.1)

35 (7.5%)

326 (69.7%)

107 (22.9%)

69.1 (23.8–189.9)

22 (4.7%)

230 (49.1%)

216 (46.2%)

27.70 (25.4–30.9)

151 (32.3%)

208 (44.4%)

109 (23.3%)

52 (11.1%)

5 (1.1%)

411 (87.8%)

468 (20.6%)

ASCENT 2

Descriptive statistics of the 2267 mCRPC patients enrolled in the control arm of five RCTs (ASCENT 2, CELGENE/MAINSAIL, VENICE, ENTHUSE 33, ENTHUSE 14).

Grouping

TABLE 1

MODONUTTI
1297

|
Abbreviations: ALP, alkaline phosphatase; ALT, alanine transaminase; AST, aspartate transaminase; BMI, body mass index; ECOG performance status, Eastern Cooperative Oncology Group performance status;
IQR, interquartile range; mCRPC, metastatic castration‐resistant prostate cancer; PLT, platelets; PSA, prostate‐specific antigen; RCTs, randomized clinical trials; WBC, white blood cells.

<0.001
2.35 (2.3–2.4)
2.35 (2.3–2.5)
2.33 (2.2–2.4)
2.30 (2.2–2.4)
2.37 (2.3–2.5)
2.4 (2.3–2.4)
Calcium, mmol/L (median [IQR])

<0.001
132.00 (83.0–224.3)
158.00 (99.5–334.0)
136.00 (85.0–273.0)
125.0 (82.0–269.0)
113.0 (80.0–213.0)
132.0 (85.0–263.0)
ALP, U/L (median [IQR])

7.0 (5.0–9.0)
5.0 (5.0–7.0)
8.6 (6.0–10.9)
6.0 (4.0–8.0)
7.0 (5.0–9.0)
7.0 (5.0–9.0)
Total bilirubin, Umol/L (median [IQR])

p
24.0 (19.0–29.0)

ENTHUSE 14
ENTHUSE 33

25.0 (20.0–33.0)
25.0 (20.0–33.0)

VENICE
CELGENE/MAINSAIL

24.0 (19.0–31.0)
24.0 (20.0–31.0)

ASCENT 2
Overall

24.0 (20.0–31.0)
AST, U/L (median [IQR])

Grouping

(Continued)
TABLE 1

<0.001

MODONUTTI
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our knowledge, previous models failed to observe a statistically
significant association between BMI and OS in mCRPC patients. This
might be due to the limited sample size in previous reports. In the
literature, there is evidence about the protective role of BMI on the
survival of metastatic prostate cancer patients, but the underlying
mechanism involved is still unclear.24,25 One reasonable hypothesis is
that the patients with high BMI show a better survival because of a
higher lean‐to‐fat ratio that puts them at a lower risk of sarcopenia.26
That said, a full understanding of the mechanisms of this relationship
is beyond the scope of this study. Finally, our results highlight the
striking heterogeneity of outcomes in patients with mCRPC, as those
in the high‐risk group, based on our new model classification, and
have almost half the survival rate of their counterparts in the low‐risk
group for the same time point. Thus, models and trials not accounting
for the heterogeneity in the baseline features represented in our
nomogram risk producing significantly biased outcomes.
Our multi‐trial design (total of five trials), using random splitting to
develop our training and validation subcohorts, significantly improves the
generalizability of our novel model. In comparison, the only other
contemporary trial‐based nomogram, which was published by Halabi
et al.12 was based on a single trial for training and a separate trial for
validation. Although the Halabi et al. model is one of the best developed
nomograms in current literature, its generalizability might be limited by
the aforementioned factors. These trials do have eligibility criteria and
may not be representative of all patients in the clinical setting, however,
randomized trials are meant to capture a random selection, which may
allow for a broader capture of samples. In addition, compared to previous
prognostic models, our nomogram has great potential as an updated and
generalizable prognostic tool. The sample sized used in our nomogram is
greater in both training and validation arms, more than twice the amount
in the widely utilized Halabi nomogram. Together, the random splitting of
cohorts and the large sample size allows for a more generalizability of use
for our nomogram.
Our results are even more interesting, because patients in our
study are chemonaïve at the time of randomization and underwent
only the standard chemotherapy with docetaxel or standard
supportive/palliative treatment, representing, in this way, a proxy
of the natural history of the disease in contemporary patients. This
means that our nomogram could be useful to define subgroups of
patients, based on the clinical risk, to use in future clinical trials. This
applicability to outline subgroups of patients based on clinical risk
factors amplifies the generalizability of our nomogram for use in
future and real‐world patients.
In this study, we used the same data set that Guinney et al.16
employed in their open‐data, crowdsourced, DREAM challenge. Their
model showed an excellent prognostic accuracy that outperformed
all previously developed models. Having said that, such a complex
model can hardly find a place in the daily busy clinical practice. The
model herein presented, instead, using a relatively small number of
readily available variables, represents a more straightforward
prognostic tool, whether it is used for clinical or research purposes.
The development of nomograms is usually designed using similar
covariates and there seems to be a knowledge gap in the analysis
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TABLE 2
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Univariable and multivariable Cox regression analysis predicting OS in 1587 patients (training cohort) with mCRPC.
Multivariable analysis
Univariable analysis

Overall model

Final model

HR

95% CI

p

HR

95% CI

p

HR

95% CI

p

White

REF

—

—

—

—

—

—

—

—

Asian

1.20

0.96–1.50

0.11

Others

0.99

0.75–1.31

0.94

—

—

—

0.97

0.95–0.99

0.0022

—

—

—

1.00

1.00–1.00

0.0002

Race

Age (years)

0.15

18–64*

REF

—

—

—

—

—

65‐74

0.99

0.83–1.17

0.88

1.04

0.87–1.25

0.64

1.24

1.02–1.50

0.03

1.21

0.99–1.48

0.065

0.78

0.70–0.87

<0.0001

0.97

0.96–0.99

0.0062

≥75
2

BMI (kg/m )
ECOG performance status

0.15

0*

REF

—

—

—

—

—

1

1.41

1.21–1.63

<0.0001

1.16

0.99–1.35

0.07

2

2.54

1.75–3.70

<0.0001

1.26

0.84–1.90

0.26

1.05

1.03–1.06

<0.0001

1.00

1.00–1.00

0.0007

PSA (ng/ml)
Site of metastasis

0.016

0.027

Bone w/o lymph nodes

REF

—

—

—

—

—

—

—

—

Lymph nodes only

0.70

0.50–1.00

0.05

1.12

0.77–1.61

0.55

1.11

0.77–1.60

0.55

Visceral

1.29

1.11–1.50

0.001

1.26

1.08–1.47

0.0042

1.24

1.06–1.44

0.0073

9

WBC (10 /L)

1.06

0.98–1.16

0.15

Neutrophils (109/L)

1.08

1.00–1.17

0.04

1.03

0.94–1.12

0.50

Hemoglobin (g/dl)

0.52

0.47–0.58

<0.0001

<11 g/dl*

REF

—

—

—

—

—

—

—

—

11‐12.9 g/dl

0.39

0.32–0.48

<0.0001

0.58

0.46–0.72

<0.0001

0.54

0.44–0.66

<0.0001

≥13 g/dl

0.27

0.22–0.34

<0.0001

0.45

0.35–0.58

<0.0001

0.41

0.32–0.51

<0.0001

PLT (10 /L)

1.20

1.10–1.31

<0.0001

1.06

0.97–1.16

0.20

Creatinine (μmol/L)

1.07

0.99–1.17

0.09

ALT (U/L)

1.02

0.97–1.07

0.48

AST (U/L)

1.10

1.08–1.13

<0.0001

1.01

1.00–1.01

0.0001

1.01

1.00–1.01

<0.0001

Total bilirubin (Umol/L)

0.92

0.85–1.00

0.06

ALP (U/L)

1.14

1.11–1.17

<0.0001

1.00

1.00–1.01

<0.0001

1.00

1.00–1.01

<0.0001

Calcium (mmol/L)

0.87

0.82–0.93

<0.0001

0.60

0.15–2.35

0.31

9

<0.0001

<0.0001

Note: Univariable and multivariable Cox regression analysis predicting OS in 1587 patients (training cohort) with mCRPC, who underwent systemic
chemotherapy with docetaxel plus glucocorticoid or standard supportive/palliative treatment.
Abbreviations: ALP, alkaline phosphatase; ALT, alanine transaminase; AST, aspartate transaminase; BMI, body mass index; CI, confidence interval; ECOG
performance status, Eastern Cooperative Oncology Group performance status; HR, hazard ratio; mCRPC, metastatic castration‐resistant prostate cancer;
OS, overall survival; PLT, platelets; PSA, prostate‐specific antigen; WBC, white blood cells.

among them. Researchers are continually seeking to analyze which

distant year of diagnosis, greater number of bone metastasis, higher

covariates contribute to OS when they are constructing nomograms.

PSA levels and shorter PSA doubling time were associated with worse

In a recent study investing predictors from time of diagnosis of

OS. Halabi et al.12 saw worse outcomes with poor performance

mCRPC to all‐cause mortality, Moreira et al.13 found that age, greater

status, visceral metastasis, higher lactate dehydrogenase, more opioid
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F I G U R E 2 Novel nomogram predicting the overall survival (OS) at 12 and 24 months of metastatic castration‐resistant prostate cancer
(mCRPC) patients undergoing systemic chemotherapy with docetaxel plus glucocorticoids or standard supportive/palliative treatment.

F I G U R E 3 Time‐dependent area under the curve (tAUC) of the training cohort, validation cohort, and the entire cohort. [Color figure can be
viewed at wileyonlinelibrary.com]

analgesic use, lower serum albumin, lower hemoglobin, higher PSA

Our study is not devoid of limitations. For example, as we did not

levels, and higher ALP. Our validation compared similar covariates yet

have access to data of patients enrolled in the interventional arms,

found that bone metastasis was not associated significantly

we are unable to estimate the effect of the experimental therapy on

associated with worse OS. These differences among factors influen-

the OS of these patients. Secondly, we understand that the clinical

cing OS from various studies is a knowledge gap in the creation of

trials used do have eligibility criteria and may not be representative of

nomograms that require more detailed analysis.

all patients in the clinical setting. Thirdly, the accuracy of our model is

MODONUTTI
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F I G U R E 4 (A) Calibration curves of the actual probability of survival versus the predicted probability of overall survival (OS) at 12, 24,
36, and 48 months obtained using the validation cohort (n = 1587 patients). The dashed black line describes an ideal test, the continuous black
line represents the prediction of our model, and the black bars on the top of each plot denote the distribution of predicted probabilities.
(B) Calibration curves of the actual probability of survival versus the predicted probability of OS at 12, 24, 36, and 48 months obtained using the
test cohort (n = 680 patients). The dashed black line describes an ideal test, the continuous black line represents the prediction of our model, and
the black bars on the top of each plot denote the distribution of predicted probabilities.
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F I G U R E 5 Kaplan–Meier survival curves depicting overall survival (OS) of low‐risk versus high‐risk patients (stratified based on the
nomogram predicted median OS in the training cohort) enrolled in the training (A) and validation (B) cohorts. [Color figure can be viewed at
wileyonlinelibrary.com]

not perfect. This observation could be due to presence of other
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their weight on the survival of mCRPC patients. A further limitation
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